Phase Forward to Host Eighth Annual International Users Conference, November 3-5, Boston

Conference to Showcase Customer Successes, Major Product Releases and Recent Acquisitions, and Provide Forum for Networking and Sharing Best Practices

• Press Release
• Source: Phase Forward
• On 9:00 am EST, Monday November 2, 2009

WALTHAM, Mass.--(BUSINESS WIRE)--Phase Forward (NASDAQ: PFWD - News), a leading provider of data management solutions for clinical trials and drug safety, will host its eighth annual International Users Conference (IUC) this week. Under the theme “Powering More Possibilities,” the conference will be held at the Sheraton Boston Hotel in Boston.

Related Quotes

Symbol	Price	Change
PFWD	15.48	-0.43

{"s" : "pfwd","k" : "c10,l10,p20,t10","o" : "","j" : ""}

Former CEO of Novazyme Pharmaceuticals, Inc. and president and CEO of Amicus Therapeutics, John F. Crowley will deliver the opening keynote address during which he will discuss his personal journey to find a cure for Pompe disease and his experience in bringing new therapies to market. After his two youngest children were diagnosed with Pompe disease, he decided to leave his post at Bristol-Myers Squibb to become Novazyme’s CEO, where he ultimately helped the company develop a therapy for Pompe disease. In 2001 Novazyme merged into Genzyme Corporation.

An additional keynote will be delivered by P. K. Tandon, Ph.D., senior vice president, global biomedical data sciences and informatics at Genzyme Corporation. Dr. Tandon joined Genzyme in 1997 and is responsible for leading a global group encompassing biostatistics, data management, statistical programming, electronic data submissions and data capture, information systems and medical writing.

A third keynote will be given by Charles Cooper, M.D., medical officer of the Office of Translational Sciences Center for Drug Evaluation and Research (CDER) at FDA. In his presentation, Dr. Cooper will discuss the challenges and future directions of computational science at CDER.

“The annual conference offers an opportunity for peer-to-peer networking and learning,” said Bob Weiler, chairman and CEO, Phase Forward. “It is within this forum that we can highlight the vision and continued success of our customers and partners, and discuss the ways in which we can continue to deliver the types of products and services they need to focus on the critical work of bringing new and improved therapies to market.”

The conference will also offer:

• Four pre-conference workshops developed to offer customers insights into combining Phase Forward’s IRT and InForm™ systems, efficiently transforming clinical data collected with InForm into SDTM format, as well as an update on the capabilities of the company’s Empirica™ Signal and Empirica™ Trace products.
• More than 30 customer-driven sessions with three concurrent tracks, including a dedicated track focused on safety and strategic pharmacovigilance. Topics include the implementation, integration and optimization of solutions in the areas of study design and standards, EDC, IRT, ePRO, data integration, and clinical data repositories to support integrated data analysis.
• A partner exhibit area featuring sponsors AG Mednet, Akamai Technologies, Sentrx and the Uppsala Monitoring Centre.
• A demo room highlighting Phase Forward’s Integrated Clinical Research Suite.

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 300 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, SGS, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.

Phase Forward
Elaine Maynard, 781-902-4371
elaine.maynard@phaseforward.com
or
CHEN PR, Inc.
Meghan Locke, 781-672-3147
mlocke@chenpr.com